Lipid-based nanoformulations in the treatment of neurological disorders

References

• Abdelbary G, Fahmy RH. 2009. Diazepam-loaded solid lipid nanoparticles: design and characterization. AAPS PharmSciTech. 10(1):211–219.
   PubMed Web of Science ®Google Scholar
• Ahmad N, Ahmad R, Alam MA, Ahmad FJ, Amir M, Pottoo FH, Sarafroz M, Jafar M, Umar K. 2019. Daunorubicin oral bioavailability enhancement by surface coated natural biodegradable macromolecule chitosan based polymeric nanoparticles. Int J Biol Macromol. 128:825–838.
   PubMed Web of Science ®Google Scholar
• Alam MI, Baboota S, Ahuja A, Ali M, Ali J, Sahni JK. 2013. Intranasal infusion of nanostructured lipid carriers (NLC) containing CNS acting drug and estimation in brain and blood. Drug Deliv. 20(6):247–251.
   PubMed Web of Science ®Google Scholar
• Alam MS, Garg A, Pottoo FH, Saifullah MK, Tareq AI, Manzoor O, Mohsin M, Javed MN. 2017. Gum ghatti mediated, one pot green synthesis of optimized gold nanoparticles: Investigation of process-variables impact using Box-Behnken based statistical design. Int J Biol Macromol. 104:758–767.
   PubMed Web of Science ®Google Scholar
• Alam MS, Javed MN, Pottoo FH, Waziri A, Almalki FA, Hasnain MS, Garg A, Saifullah MK. n.d. QbD approached comparison of reaction mechanism in microwave synthesized gold nanoparticles and their superior catalytic role against hazardous nirto-dye. Appl Organometal Chem. 0:e5071.
   Google Scholar
• Alam T, Pandit J, Vohora D, Aqil M, Ali A, Sultana Y. 2015. Optimization of nanostructured lipid carriers of lamotrigine for brain delivery: in vitro characterization and in vivo efficacy in epilepsy. Expert Opin Drug Deliv. 12(2):181–194.
   PubMed Web of Science ®Google Scholar
• Ali Khan A, Mudassir J, Mohtar N, Darwis Y. 2013. Advanced drug delivery to the lymphatic system: lipid-based nanoformulations. Int J Nanomed. 8:2733–2744.
   PubMed Web of Science ®Google Scholar
• Barkat MA, Beg S, Pottoo FH, Ahmad FJ. 2019. Nanopaclitaxel therapy: an evidence based review on the battle for next-generation formulation challenges. Nanomedicine (Lond). 14(10):1323–1341.
   PubMed Web of Science ®Google Scholar
• Barkat MA, Harshita FN, Beg S, Pottoo FH, Garg A, Singh SP, Ahmad FJ. 2019. Silver nanoparticles and their antimicrobial applications. CNANOM. 8(3):215–224.
   Google Scholar
• Battaglia L, Serpe L, Foglietta F, Muntoni E, Gallarate M, Rodriguez ADP, Solinis MA. 2016. Application of lipid nanoparticles to ocular drug delivery. Expert Opinion Drug Deliv. 13(12):1743–1757.
   PubMed Web of Science ®Google Scholar
• Birbeck GL. 2010. Epilepsy care in developing countries: part I of II. Epilepsy Curr. 10(4):75–79.
   PubMed Web of Science ®Google Scholar
• Bodor n, Buchwald n. 1999. Recent advances in the brain targeting of neuropharmaceuticals by chemical delivery systems. Adv Drug Deliv Rev. 36(2–3):229–254.
   PubMed Web of Science ®Google Scholar
• Bondi ML, Montana G, Craparo EF, Picone P, Capuano G, Carlo MD, Giammona G. 2009. Ferulic acid-loaded lipid nanostructures as drug delivery systems for Alzheimer’s disease: preparation, characterization and cytotoxicity studies. Curr Nanosci. 5(1):26–32.
   Web of Science ®Google Scholar
• Bramini M, Ye D, Hallerbach A, Nic Raghnaill M, Salvati A, Åberg C, Dawson KA. 2014. Imaging approach to mechanistic study of nanoparticle interactions with the blood–brain barrier. ACS Nano. 8(5):4304–4312.
   PubMed Web of Science ®Google Scholar
• Castellani RJ, Rolston RK, Smith MA. 2010. Alzheimer disease. Dis Mon. 56(9):484–546.
   PubMed Web of Science ®Google Scholar
• Chan H-K, Kwok PCL. 2011. Production methods for nanodrug particles using the bottom-up approach. Adv Drug Deliv Rev. 63(6):406–416.
   PubMed Web of Science ®Google Scholar
• Chen H, Yoshioka H, Kim GS, Jung JE, Okami N, Sakata H, Maier CM, Narasimhan P, Goeders CE, Chan PH. 2011. Oxidative stress in ischemic brain damage: mechanisms of cell death and potential molecular targets for neuroprotection. Antioxid Redox Signal. 14(8):1505–1517.
   PubMed Web of Science ®Google Scholar
• Chen X, Pan W. 2015. The treatment strategies for neurodegenerative diseases by integrative medicine. Integr Med Int. 1(4):223–225.
   Google Scholar
• Cingolani GM, Di Stefano A, Mosciatti B, Napolitani F, Giorgioni G, Ricciutelli M, Claudi F. 2000. Synthesis of L-(+)-3-(3-hydroxy-4-pivaloyloxybenzyl)-2,5-diketomorpholine as potential prodrug of L-dopa. Bioorg Med Chem Lett. 10(12):1385–1388.
   PubMed Web of Science ®Google Scholar
• Connolly BS, Lang AE. 2014. Pharmacological treatment of Parkinson disease: a review. JAMA. 311(16):1670–1683.
   PubMed Web of Science ®Google Scholar
• Daneman R, Prat A. 2015. The blood–brain barrier. Cold Spring Harb Perspect Biol. 7(1):a020412.
   PubMed Web of Science ®Google Scholar
• Dauer W, Przedborski S. 2003. Parkinson’s disease: mechanisms and models. Neuron. 39(6):889–909.
   PubMed Web of Science ®Google Scholar
• Deb P, Sharma S, Hassan KM. 2010. Pathophysiologic mechanisms of acute ischemic stroke: an overview with emphasis on therapeutic significance beyond thrombolysis. Pathophysiology. 17(3):197–218.
   PubMedGoogle Scholar
• Debnath SK, Saisivam S, Debanth M, Omri A. 2018. Development and evaluation of Chitosan nanoparticles based dry powder inhalation formulations of prothionamide. PLOS One. 13(1):e0190976.
   PubMed Web of Science ®Google Scholar
• Dehouck B, Fenart L, Dehouck MP, Pierce A, Torpier G, Cecchelli R. 1997. A new function for the LDL receptor: transcytosis of LDL across the blood-brain barrier. J. Cell Biol. 138(4):877–889.
   PubMed Web of Science ®Google Scholar
• Engelborghs S, D'Hooge R, De Deyn PP. 2000. Pathophysiology of epilepsy. Acta Neurol Belg. 100(4):201–213.
   PubMed Web of Science ®Google Scholar
• Eskandari S, Varshosaz J, Minaiyan M, Tabbakhian M. 2011. Brain delivery of valproic acid via intranasal administration of nanostructured lipid carriers: in vivo pharmacodynamic studies using rat electroshock model. Int J Nanomed. 6:363–371.
   PubMed Web of Science ®Google Scholar
• Esposito E, Fantin M, Marti M, Drechsler M, Paccamiccio L, Mariani P, Sivieri E, Lain F, Menegatti E, Morari M, et al. 2008. Solid lipid nanoparticles as delivery systems for bromocriptine. Pharm Res. 25(7):1521–1530.
   PubMed Web of Science ®Google Scholar
• Ezzati Nazhad Dolatabadi J, Omidi Y. 2016. Solid lipid-based nanocarriers as efficient targeted drug and gene delivery systems. Trac Trends Anal Chem. 77:100–108.
   Web of Science ®Google Scholar
• Fatouh AM, Elshafeey AH, Abdelbary A. 2017. Intranasal agomelatine solid lipid nanoparticles to enhance brain delivery: formulation, optimization and in vivo pharmacokinetics. DDDT. 11:1815–1825.
   PubMed Web of Science ®Google Scholar
• Fisher RS, Acevedo C, Arzimanoglou A, Bogacz A, Cross JH, Elger CE, Engel J, Forsgren L, French JA, Glynn M, et al. 2014. ILAE official report: a practical clinical definition of epilepsy. Epilepsia. 55(4):475–482.
   PubMed Web of Science ®Google Scholar
• Fisher RS, van Emde Boas W, Blume W, Elger C, Genton P, Lee P, Engel J. 2005. Epileptic seizures and epilepsy: definitions proposed by the International League Against Epilepsy (ILAE) and the International Bureau for Epilepsy (IBE). Epilepsia. 46(4):470–472.
   PubMed Web of Science ®Google Scholar
• Frozza RL, Salbego C, Bernardi A, Hoppe JB, Meneghetti A, Battastini AM, Guterres S, Pohlmann A. 2011. Incorporation of resveratrol into lipid-core nanocapsules improves its cerebral bioavailability and reduces the Aβ-induced toxicity. Alzheimer Dement. 7:S114.
   Google Scholar
• Gandhi S, Wood NW. 2005. Molecular pathogenesis of Parkinson’s disease. Hum Mol Genet. 14(18):2749–2755.
   Web of Science ®Google Scholar
• Gao Y, Gu W, Chen L, Xu Z, Li Y. 2008. The role of daidzein-loaded sterically stabilized solid lipid nanoparticles in therapy for cardio-cerebrovascular diseases. Biomaterials. 29(30):4129–4136.
   PubMed Web of Science ®Google Scholar
• Gartziandia O, Herran E, Pedraz JL, Carro E, Igartua M, Hernandez RM. 2015. Chitosan coated nanostructured lipid carriers for brain delivery of proteins by intranasal administration. Colloids Surf B Biointerfaces. 134:304–313.
   PubMed Web of Science ®Google Scholar
• GBD 2015 Neurological Disorders Collaborator Group. 2017. Global, regional, and national burden of neurological disorders during 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet Neurol. 16:877–897.
   PubMed Web of Science ®Google Scholar
• Ghaffari M, Dolatabadi JEN. 2019. Nanotechnology for pharmaceuticals. In: Thomas S, Grohens Y, Pottathara YB, editors. Industrial applications of nanomaterials, micro and nano technologies. Netherlands: Elsevier; p. 475–502.
   Google Scholar
• Girault J-A, Greengard P. 2004. The neurobiology of dopamine signaling. Arch Neurol. 61(5):641–644.
   PubMedGoogle Scholar
• Gomes dos Reis L, Lee W-H, Svolos M, Moir LM, Jaber R, Windhab N, Young PM, Traini D. 2019. Nanotoxicologic Effects of PLGA nanoparticles formulated with a cell-penetrating peptide: searching for a safe pDNA delivery system for the lungs. Pharmaceutics. 11(1):12.
   PubMed Web of Science ®Google Scholar
• Hardy J. 1999. Pathways to primary neurodegenerative disease. Mayo Clinic Proc. 74(8):835–837.
   PubMed Web of Science ®Google Scholar
• Harshita Barkat MA, Rizwanullah M, Beg S, Pottoo FH, Siddiqui S, Ahmad FJ. 2019. Paclitaxel-loaded nanolipidic carriers with improved oral bioavailability and anticancer activity against human liver carcinoma. AAPS PharmSciTech. 20:87.
   PubMed Web of Science ®Google Scholar
• Hasnain MS, Javed MN, Alam MS, Rishishwar P, Rishishwar S, Ali S, Nayak AK, Beg S. 2019. Purple heart plant leaves extract-mediated silver nanoparticle synthesis: optimization by Box-Behnken design. Mater Sci Eng C. 99:1105–1114.
   PubMed Web of Science ®Google Scholar
• Hassanzadeh P, Arbabi E, Atyabi F, Dinarvand R. 2018. Ferulic acid-loaded nanostructured lipid carriers: a promising nanoformulation against the ischemic neural injuries. Life Sci. 193:64–76.
   PubMed Web of Science ®Google Scholar
• Hassanzadeh P, Atyabi F, Dinarvand R, Dehpour A-R, Azhdarzadeh M, Dinarvand M. 2017. Application of nanostructured lipid carriers: the prolonged protective effects for sesamol in in vitro and in vivo models of ischemic stroke via activation of PI3K signalling pathway. Daru. 25(1):25.
   PubMed Web of Science ®Google Scholar
• Hernando S, Herran E, Figueiro-Silva J, Pedraz JL, Igartua M, Carro E, Hernandez RM. 2018. Intranasal administration of TAT-conjugated lipid nanocarriers loading GDNF for Parkinson’s disease. Mol Neurobiol. 55(1):145–155.
   PubMed Web of Science ®Google Scholar
• Huang H-C, Chang P, Dai X-L, Jiang Z-F. 2012. Protective effects of curcumin on amyloid-β-induced neuronal oxidative damage. Neurochem Res. 37(7):1584–1597.
   PubMed Web of Science ®Google Scholar
• Jafari B, Pourseif MM, Barar J, Rafi MA, Omidi Y. 2019. Peptide-mediated drug delivery across the blood-brain barrier for targeting brain tumors. Expert Opin Drug Deliv. 16(6):583–605.
   PubMed Web of Science ®Google Scholar
• Jaiswal P, Gidwani B, Vyas A. 2016. Nanostructured lipid carriers and their current application in targeted drug delivery. Artif Cells Nanomed Biotechnol. 44(1):27–40.
   PubMed Web of Science ®Google Scholar
• Jankovic J, Stacy M. 2007. Medical management of levodopa-associated motor complications in patients with Parkinson’s disease. CNS Drugs. 21(8):677–692.
   PubMed Web of Science ®Google Scholar
• Javed MN, Alam MS, Waziri A, Pottoo FH, Yadav AK, Hasnain MS, Almalki FA. 2019. QbD applications for the development of nanopharmaceutical products. In: Beg S, Hasnain MS, editors. Pharmaceutical quality by design. London: Academic Press; p. 229–253.
   Google Scholar
• Javed MN, Kohli K, Amin S. 2018. Risk assessment integrated QbD approach for development of optimized bicontinuous mucoadhesive limicubes for oral delivery of rosuvastatin. AAPS PharmSciTech. 19(3):1377–1391.
   PubMed Web of Science ®Google Scholar
• Jazuli I, Annu Null Nabi B, Moolakkadath T, Alam T, Baboota S, Ali J. 2019. Optimization of nanostructured lipid carriers of lurasidone hydrochloride using Box-Behnken design for brain targeting: in vitro and in vivo studies. J Pharm Sci. 108(9):3082–3090.
   PubMed Web of Science ®Google Scholar
• Kakkar V, Muppu SK, Chopra K, Kaur IP. 2013. Curcumin loaded solid lipid nanoparticles: an efficient formulation approach for cerebral ischemic reperfusion injury in rats. Eur J Pharm Biopharm. 85(3):339–345.
   PubMed Web of Science ®Google Scholar
• Karantzoulis S, Galvin JE. 2011. Distinguishing Alzheimer’s disease from other major forms of dementia. Expert Rev Neurother. 11(11):1579–1591.
   PubMed Web of Science ®Google Scholar
• Kaushik D. 2016. Baicalein loaded polysorbate 80 nanostructured lipid carriers offered enhanced stability and in vitro drug release. Asian J Pharm. 10(2):S128–S133.
   Web of Science ®Google Scholar
• Koh SH, Lo EH. 2015. The role of the PI3K pathway in the regeneration of the damaged brain by neural stem cells after cerebral infarction. J Clin Neurol. 11(4):297–304.
   PubMed Web of Science ®Google Scholar
• Kreuter J. 2002. Transport of drugs across the blood-brain barrier by nanoparticles. J Control Release. 161(2):264–273.
   Google Scholar
• Kreuter J. 2001. Nanoparticulate systems for brain delivery of drugs. Adv Drug Deliv Rev. 47(1):65–81.
   PubMed Web of Science ®Google Scholar
• Kumbhar DD, Pokharkar VB. 2013. Engineering of a nanostructured lipid carrier for the poorly water-soluble drug, bicalutamide: Physicochemical investigations. Colloids Surf A. 416:32–42.
   Web of Science ®Google Scholar
• Kundu P, Das M, Tripathy K, Sahoo SK. 2016. Delivery of dual drug loaded lipid based nanoparticles across the blood-brain barrier impart enhanced neuroprotection in a rotenone induced mouse model of parkinson’s disease. ACS Chem Neurosci. 7(12):1658–1670.
   PubMed Web of Science ®Google Scholar
• Leyva-Gómez G, González-Trujano ME, López-Ruiz E, Couraud P-O, Wekslerg B, Romero I, Miller F, Delie F, Allémann E, Quintanar-Guerrero D. 2014. Nanoparticle formulation improves the anticonvulsant effect of clonazepam on the pentylenetetrazole-induced seizures: behavior and electroencephalogram. J Pharm Sci. 103(8):2509–2519.
   PubMed Web of Science ®Google Scholar
• Li F, Weng Y, Wang L, He H, Yang J, Tang X. 2010. The efficacy and safety of bufadienolides-loaded nanostructured lipid carriers. Int J Pharm. 393(1-2):203–211.
   PubMed Web of Science ®Google Scholar
• Liu Z, Zhang L, He Q, Liu X, Okeke CI, Tong L, Guo L, Yang H, Zhang Q, Zhao H, et al. 2015. Effect of Baicalin-loaded PEGylated cationic solid lipid nanoparticles modified by OX26 antibody on regulating the levels of baicalin and amino acids during cerebral ischemia-reperfusion in rats. Int J Pharm. 489(1-2):131–138.
   PubMed Web of Science ®Google Scholar
• Löscher W, Potschka H. 2005. Drug resistance in brain diseases and the role of drug efflux transporters. Nat Rev Neurosci. 6(8):591–602.
   PubMed Web of Science ®Google Scholar
• Loureiro JA, Andrade S, Duarte A, Neves AR, Queiroz JF, Nunes C, Sevin E, Fenart L, Gosselet F, Coelho MAN, et al. 2017. Resveratrol and grape extract-loaded solid lipid nanoparticles for the treatment of Alzheimer’s disease. Molecules. 22(2):277.
   PubMed Web of Science ®Google Scholar
• Lu Y, Huang J, Wang H, Lou X, Liao M, Hong L, Tao R, Ahmed MM, Shan C, Wang X, et al. 2014. Targeted therapy of brain ischaemia using Fas ligand antibody conjugated PEG-lipid nanoparticles. Biomaterials. 35(1):530–537.
   PubMed Web of Science ®Google Scholar
• Luo Y, Chen D, Ren L, Zhao X, Qin J. 2006. Solid lipid nanoparticles for enhancing vinpocetine’s oral bioavailability. J Control Release. 114(1):53–59.
   PubMed Web of Science ®Google Scholar
• Madrid Y, Langer LF, Brem H, Langer R. 1991. New directions in the delivery of drugs and other substances to the central nervous system. Adv Pharmacol. 22:299–324.
   PubMedGoogle Scholar
• Marambaud P, Vingtdeux V, Giliberto L, Zhao H, Chandakkar P, Wu Q, Simon JE, Janle EM, Lobo J, Ferruzzi MG, et al. 2010. Resveratrol lowers beta-amyloid accumulation and deposition in vivo by controlling AMPK signaling. Alzheimer’s Dement. 6:S406.
   Google Scholar
• Masserini M. 2013. Nanoparticles for brain drug delivery [WWW document]. Int Sch Res Notices. 2013:238428.
   Google Scholar
• Mehnert W, Mäder K. 2012. Solid lipid nanoparticles: production, characterization and applications. Adv Drug Deliv Rev. 64:83–101.
   Web of Science ®Google Scholar
• Mehnert W, Mäder K. 2001. Solid lipid nanoparticles: production, characterization and applications. Adv Drug Deliv Rev. 47(2-3):165–196.
   PubMed Web of Science ®Google Scholar
• Mishra S, Sharma S, Javed MN, Pottoo FH, Abul Barkat M, Harshita Null Amir M, Sarfaroz M. 2019. Bioinspired nanocomposites: applications in disease diagnosis and treatment. Pharm Nanotechnol. 7(3):206–209.
   PubMedGoogle Scholar
• Misra A, Ganesh S, Shahiwala A, Shah SP. 2003. Drug delivery to the central nervous system: a review. J Pharm Pharm Sci. 6(2):252–273.
   PubMed Web of Science ®Google Scholar
• Moore DJ, West AB, Dawson VL, Dawson TM. 2005. Molecular pathophysiology of Parkinson’s disease. Annu Rev Neurosci. 28(1):57–87.
   PubMed Web of Science ®Google Scholar
• Morsi NM, Ghorab DM, Badie HA. 2013. Brain targeted solid lipid nanoparticles for brain ischemia: preparation and in vitro characterization. Pharm Dev Technol. 18(3):736–744.
   PubMed Web of Science ®Google Scholar
• Moshé SL, Perucca E, Ryvlin P, Tomson T. 2015. Epilepsy: new advances. Lancet. 385(9971):884–898.
   PubMed Web of Science ®Google Scholar
• Moskowitz MA, Lo EH, Iadecola C. 2010. The science of stroke: mechanisms in search of treatments. Neuron. 67(2):181–198.
   PubMed Web of Science ®Google Scholar
• Motawea A, Borg T, El-Gawad AE-GHA. 2018. Topical phenytoin nanostructured lipid carriers: design and development. Drug Dev Ind Pharm. 44(1):144–157.
   PubMed Web of Science ®Google Scholar
• Moustafa RR, Baron J-C. 2009. Pathophysiology of ischaemic stroke: insights from imaging, and implications for therapy and drug discovery. Br J Pharmacol. 153(S1):S44–S54.
   Web of Science ®Google Scholar
• Mukherjee S, Ray S, Thakur R.S. 2009. Solid lipid nanoparticles: a modern formulation approach in drug delivery system. Indian J Pharm Sci. 71(4):349–358.
   PubMed Web of Science ®Google Scholar
• Müller RH, Radtke M, Wissing SA. 2002. Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations. Adv Drug Deliv Rev. 54 (Suppl 1):S131–S155.
   PubMed Web of Science ®Google Scholar
• Muntimadugu E, Dhommati R, Jain A, Challa VGS, Shaheen M, Khan W. 2016. Intranasal delivery of nanoparticle encapsulated tarenflurbil: a potential brain targeting strategy for Alzheimer’s disease. Eur J Pharm Sci. 92:224–234.
   PubMed Web of Science ®Google Scholar
• Nabi B, Rehman S, Baboota S, Ali J. 2019. Insights on oral drug delivery of lipid nanocarriers: a win-win solution for augmenting bioavailability of antiretroviral drugs. AAPS PharmSciTech. 20(2):60.
   PubMed Web of Science ®Google Scholar
• Nair R, Kumar AC, Priya VK, Yadav CM, Raju PY. 2012. Formulation and evaluation of chitosan solid lipid nanoparticles of carbamazepine. Lipids Health Dis. 11(1):72.
   PubMed Web of Science ®Google Scholar
• Naseri N, Valizadeh H, Zakeri-Milani P. 2015. Solid lipid nanoparticles and nanostructured lipid carriers: structure, preparation and application. Adv Pharm Bull. 5(3):305–313.
   PubMed Web of Science ®Google Scholar
• Neves AR, Queiroz JF, Reis S. 2016. Brain-targeted delivery of resveratrol using solid lipid nanoparticles functionalized with apolipoprotein E. J Nanobiotechnol. 14(1):27.
   PubMed Web of Science ®Google Scholar
• Nigar S, Pottoo FH, Tabassum N, Verma SK, Javed MN. 2016. Molecular insights into the role of inflammation and oxidative stress in epilepsy. JAMPS. 10(1):1–9.
   Google Scholar
• Omidi Y, Barar J. 2012. Impacts of blood-brain barrier in drug delivery and targeting of brain tumors. Bioimpacts. 2(1):5–22.
   PubMedGoogle Scholar
• Ono K, Hasegawa K, Naiki H, Yamada M. 2004. Curcumin has potent anti-amyloidogenic effects for Alzheimer’s beta-amyloid fibrils in vitro. J Neurosci Res. 75(6):742–750.
   PubMed Web of Science ®Google Scholar
• Pardeshi CV, Belgamwar VS, Tekade AR, Surana SJ. 2013. Novel surface modified polymer-lipid hybrid nanoparticles as intranasal carriers for ropinirole hydrochloride: in vitro, ex vivo and in vivo pharmacodynamic evaluation. J Mater Sci Mater Med. 24(9):2101–2115.
   PubMed Web of Science ®Google Scholar
• Parikh A, Kathawala K, Tan CC, Garg S, Zhou X-F. 2017. Lipid-based nanosystem of edaravone: development, optimization, characterization and in vitro/in vivo evaluation. Drug Deliv. 24(1):962–978.
   PubMed Web of Science ®Google Scholar
• Patel PA, Patil SC, Kalaria DR, Kalia YN, Patravale VB. 2013. Comparative in vitro and in vivo evaluation of lipid based nanocarriers of Huperzine A. Int J Pharm. 446(1-2):16–23.
   PubMed Web of Science ®Google Scholar
• Patel T, Zhou J, Piepmeier JM, Saltzman WM. 2012. Polymeric nanoparticles for drug delivery to the central nervous system. Adv Drug Deliv Rev. 64(7):701–705.
   PubMed Web of Science ®Google Scholar
• Perucca E, Tomson T. 2011. The pharmacological treatment of epilepsy in adults. Lancet Neurol. 10(5):446–456.
   PubMed Web of Science ®Google Scholar
• Poovi G, Damodharan N. 2018. Lipid nanoparticles: a challenging approach for oral delivery of BCS Class-II drugs. Future J Pharm Sci. 4(2):191–205.
   Web of Science ®Google Scholar
• Pottoo FH, Barkat Md A, Harshita Ansari MA, Javed Md N, Sajid Jamal QM, Kamal MA. 2019. Nanotechnological based miRNA intervention in the therapeutic management of neuroblastoma. Seminars Cancer Biol.
   PubMed Web of Science ®Google Scholar
• Pottoo FH, Bhowmik M, Vohora D. 2014. Raloxifene protects against seizures and neurodegeneration in a mouse model mimicking epilepsy in postmenopausal woman. Eur J Pharm Sci. 65:167–173.
   PubMed Web of Science ®Google Scholar
• Pottoo FH, Javed N, Barkat MA, Alam MS, Nowshehri JA, Alshayban DM, Ansari MA. 2018. Estrogen and serotonin: Complexity of interactions and implications for epileptic seizures and epileptogenesis. Curr Neuropharmacol. 17(3):214–231.
   Web of Science ®Google Scholar
• Pottoo FH, Tabassum N, Darzi MM. 2016. Bromocriptine mesylate protects against status epilepticus and temporal lobe epilepsy: neurobehavioral, histopathological and neurochemical evidences. INDJ. 6(4):1–13.
   Google Scholar
• Pottoo FH, Tabassum N, Javed MN, Nigar S, Rasheed R, Khan A, Barkat MA, Alam MS, Maqbool A, Ansari MA, et al. 2018. The synergistic effect of raloxifene, fluoxetine, and bromocriptine protects against pilocarpine-induced status epilepticus and temporal lobe epilepsy. Mol Neurobiol. 56(2):1233–1247.
   PubMed Web of Science ®Google Scholar
• Priano L, Esposti D, Esposti R, Castagna G, De Medici C, Fraschini F, Gasco MR, Mauro A. 2007. Solid lipid nanoparticles incorporating melatonin as new model for sustained oral and transdermal delivery systems. J Nanosci Nanotech. 7(10):3596–3601.
   PubMed Web of Science ®Google Scholar
• Purvin S, Vuddanda PR, Singh SK, Jain A, Singh S. 2014. Pharmacokinetic and tissue distribution study of solid lipid nanoparticles of zidovudine in rats. J Nanotechnol. 2014:1–7.
   Google Scholar
• Qian ZM, Ke Y. 2014. Huperzine A: is it an effective disease-modifying drug for Alzheimer’s disease? Front Aging Neurosci. 6:216.
   PubMed Web of Science ®Google Scholar
• Rahman MA, Harwansh RK, Iqbal Z. 2019. Systematic development of sertraline loaded solid lipid nanoparticle (SLN) by emulsification-ultrasonication method and pharmacokinetic study in Sprague-Dawley rats. PNT. 7(2):162–176.
   Google Scholar
• Rassu G, Soddu E, Posadino AM, Pintus G, Sarmento B, Giunchedi P, Gavini E. 2017. Nose-to-brain delivery of BACE1 siRNA loaded in solid lipid nanoparticles for Alzheimer’s therapy. Colloids Surf B Biointerfaces. 152:296–301.
   PubMed Web of Science ®Google Scholar
• Rodriguez-Nogales C, Noguera R, Patrick C, Blanco-Prieto MJJ. 2019. Therapeutic opportunities in neuroblastoma using nanotechnology. J Pharmacol Exp Ther. 37(3):625–635.
   Web of Science ®Google Scholar
• Santaguida S, Janigro D, Hossain M, Oby E, Rapp E, Cucullo L. 2006. Side by side comparison between dynamic versus static models of blood-brain barrier in vitro: a permeability study. Brain Res. 1109(1):1–13.
   PubMed Web of Science ®Google Scholar
• Saupe A, Wissing SA, Lenk A, Schmidt C, Müller RH. 2005. Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) – structural investigations on two different carrier systems. Biomed Mater Eng. 15(5):393–402.
   PubMed Web of Science ®Google Scholar
• Scalia S, Young PM, Traini D. 2015. Solid lipid microparticles as an approach to drug delivery. Expert Opin Drug Deliv. 12(4):583–599.
   PubMed Web of Science ®Google Scholar
• Schlosshauer B, Steuer H. 2002. Comparative anatomy, physiology and in vitro models of the blood-brain and blood-retina barrier. Curr Med Chem. 2(3):175–186.
   Google Scholar
• Scioli Montoto S, Sbaraglini ML, Talevi A, Couyoupetrou M, Di Ianni M, Pesce GO, Alvarez VA, Bruno-Blanch LE, Castro GR, Ruiz ME, et al. 2018. Carbamazepine-loaded solid lipid nanoparticles and nanostructured lipid carriers: physicochemical characterization and in vitro/in vivo evaluation. Colloids Surf B Biointerfaces. 167:73–81.
   PubMed Web of Science ®Google Scholar
• Serrano-Pozo A, Frosch MP, Masliah E, Hyman BT. 2011. Neuropathological alterations in Alzheimer disease. Cold Spring Harb Perspect Med. 1(1):a006189–a006189.
   PubMed Web of Science ®Google Scholar
• Serteser M, Ozben T, Gumuslu S, Balkan S, Balkan E. 2002. The effects of NMDA receptor antagonist MK-801 on lipid peroxidation during focal cerebral ischemia in rats. Prog Neuro-Psychopharmacol Biol Psychiatry. 26(5):871–877.
   PubMed Web of Science ®Google Scholar
• Shah B, Khunt D, Bhatt H, Misra M, Padh H. 2015. Application of quality by design approach for intranasal delivery of rivastigmine loaded solid lipid nanoparticles: effect on formulation and characterization parameters. Eur J Pharm Sci. 78:54–66.
   PubMed Web of Science ®Google Scholar
• Sharma S, Noushad Javed M, Pottoo F, Arman Rabbani S, Barkat Md Ab H, Sarafroz D, Amir M. 2019. Bioresponse inspired nanomaterials for targeted drug and gene delivery. Pharm Nanotechnol. 7(3):220–233.
   PubMedGoogle Scholar
• Shrestha H, Bala R, Arora S. 2014. Lipid-based drug delivery systems. J Pharm. 2014:1–10.
   Google Scholar
• Shuiming Z, Dongzhi H, Qineng P, Yan X. 2010. Preparation and entrapment efficiency determination of solid lipid nanoparticles loaded levodopa. Zhongguo Yiyuan Yaoxue Zazhi. 30:1171–1175.
   Google Scholar
• Singh R, Lillard JW. 2009. Nanoparticle-based targeted drug delivery. Exp Mol Pathol. 86(3):215–223.
   PubMed Web of Science ®Google Scholar
• Sood S, Jain K, Gowthamarajan K. 2013. Curcumin-donepezil–loaded nanostructured lipid carriers for intranasal delivery in an Alzheimer’s disease model. Alzheimer Dement. 9:P299.
   Google Scholar
• Su Y, Sinko PJ. 2006. Drug delivery across the blood–brain barrier: why is it difficult? how to measure and improve it? Expert Opin Drug Deliv. 3(3):419–435.
   PubMed Web of Science ®Google Scholar
• Thal LJ, Salmon DP, Lasker B, Bower D, Klauber MR. 1989. The safety and lack of efficacy of vinpocetine in Alzheimer’s disease. J Am Geriatr Soc. 37(6):515–520.
   PubMed Web of Science ®Google Scholar
• Tran TH, Ramasamy T, Cho HJ, Kim YI, Poudel BK, Choi H-G, Yong CS, Kim JO. 2014. Formulation and optimization of raloxifene-loaded solid lipid nanoparticles to enhance oral bioavailability. J Nanosci Nanotech. 14(7):4820–4831.
   PubMed Web of Science ®Google Scholar
• Tsai M-J, Huang Y-B, Wu P-C, Fu Y-S, Kao Y-R, Fang J-Y, Tsai Y-H. 2011. Oral apomorphine delivery from solid lipid nanoparticles with different monostearate emulsifiers: pharmacokinetic and behavioral evaluations. J Pharm Sci. 100(2):547–557.
   PubMed Web of Science ®Google Scholar
• Üner M, Yener G. 2007. Importance of solid lipid nanoparticles (SLN) in various administration routes and future perspectives. Int J Nanomed. 2:289–300.
   PubMed Web of Science ®Google Scholar
• Uprit S, Kumar Sahu R, Roy A, Pare A. 2013. Preparation and characterization of minoxidil loaded nanostructured lipid carrier gel for effective treatment of alopecia. Saudi Pharm J. 21(4):379–385.
   PubMed Web of Science ®Google Scholar
• Veszelka S, Meszaros M, Kiss L, Kota Z, Pali T, Hoyk Z, Bozso Z, Fulop L, Toth A, Rakhely G, et al. 2017. Biotin and glutathione targeting of solid nanoparticles to cross human brain endothelial cells. Curr Pharm Des. 23(28):4198–4205.
   PubMed Web of Science ®Google Scholar
• Wang B-S, Wang H, Wei Z-H, Song Y-Y, Zhang L, Chen H-Z. 2009. Efficacy and safety of natural acetylcholinesterase inhibitor huperzine A in the treatment of Alzheimer’s disease: an updated meta-analysis. J Neural Transm. 116(4):457–465.
   PubMed Web of Science ®Google Scholar
• Wang JX, Sun X, Zhang ZR. 2002. Enhanced brain targeting by synthesis of 3′,5′-dioctanoyl-5-fluoro-2′-deoxyuridine and incorporation into solid lipid nanoparticles. Eur J Pharm Biopharm. 54(3):285–290.
   PubMed Web of Science ®Google Scholar
• Wavikar P, Pai R, Vavia P. 2017. Nose to brain delivery of rivastigmine by in situ gelling cationic nanostructured lipid carriers: enhanced brain distribution and pharmacodynamics. J Pharm Sci. 106(12):3613–3622.
   PubMed Web of Science ®Google Scholar
• Wohlfart S, Gelperina S, Kreuter J. 2012. Transport of drugs across the blood-brain barrier by nanoparticles. J Control Release. 161(2):264–273.
   PubMed Web of Science ®Google Scholar
• Xu L, Sun J, Lu R, Ji Q, Xu J-G. 2004. Effect of glutamate on inflammatory responses of intestine and brain after focal cerebral ischemia. WJG. 11(5):733–736.
   Web of Science ®Google Scholar
• Yang F, Lim GP, Begum AN, Ubeda OJ, Simmons MR, Ambegaokar SS, Chen PP, Kayed R, Glabe CG, Frautschy SA, et al. 2005. Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo. J Biol Chem. 280(7):5892–5901.
   PubMed Web of Science ®Google Scholar
• Yusuf M, Khan M, Khan RA, Ahmed B. 2012. Preparation, characterization, in vivo and biochemical evaluation of brain targeted piperine solid lipid nanoparticles in an experimentally induced Alzheimer’s disease model. J Drug Target. 21(3):300–311.
   PubMed Web of Science ®Google Scholar
• Zhao LN, Chiu S-W, Benoit J, Chew LY, Mu Y. 2012. The effect of curcumin on the stability of Aβ dimers. J Phys Chem B. 116(25):7428–7435.
   PubMed Web of Science ®Google Scholar
• Zhao Y-Z, Li X, Lu C-T, Lin M, Chen L-J, Xiang Q, Zhang M, Jin R-R, Jiang X, Shen X-T, et al. 2014. Gelatin nanostructured lipid carriers-mediated intranasal delivery of basic fibroblast growth factor enhances functional recovery in hemiparkinsonian rats. Nanomedicine. 10(4):755–764.
   PubMed Web of Science ®Google Scholar
• Zhong C, He M, Lou K, Gao F. 2017. The application, neurotoxicity, and related mechanism of silica nanoparticles. In: Jiang X, Gao H, editors. Neurotoxicity of nanomaterials and nanomedicine. London: Academic Press; p. 227–257.
   Google Scholar
• Zhu CW, Sano M. 2006. Economic considerations in the management of Alzheimer’s disease. Clin Interv Aging. 1(2):143–154.
   PubMed Web of Science ®Google Scholar
• Zhuang C-Y, Li N, Wang M, Zhang X-N, Pan W-S, Peng J-J, Pan Y-S, Tang X. 2010. Preparation and characterization of vinpocetine loaded nanostructured lipid carriers (NLC) for improved oral bioavailability. Int J Pharm. 394(1–2):179–185.
   PubMed Web of Science ®Google Scholar